05/25/23 4:26 PMNasdaq : ADMP acquisitionlow floatAdamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsDMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined company Combined company will have commercial products and a library of development candidates, including two clinical stage programs DPI-125, the lead development program, is a clinical stage therapeutic underRHEA-AIneutral
05/19/23 12:00 PMNasdaq : ADMP low floatAdamis Pharmaceuticals Announces Reverse Stock SplitAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., EasternRHEA-AIneutral
05/15/23 4:47 PMNasdaq : ADMP earningslow floatAdamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in various therapeuticRHEA-AIneutral
05/08/23 4:05 PMNasdaq : ADMP earningslow floatAdamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate UpdateAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatoryRHEA-AIneutral
03/16/23 4:24 PMNasdaq : ADMP earningslow floatAdamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate UpdateAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioidRHEA-AIneutral
03/14/23 4:01 PMNasdaq : ADMP earningslow floatAdamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate UpdateAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatoryRHEA-AIneutral
03/14/23 8:30 AMNasdaq : ADMP offeringlow floatAdamis Pharmaceuticals Announces $3.0 Million Registered Direct OfferingAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatoryRHEA-AIneutral
02/27/23 4:05 PMNasdaq : ADMP acquisitionlow floatAdamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of MergerCombined company will have commercial products and a library of development candidates, two of which are clinical stage Will be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhD Lead development program will be a clinical stage therapeutic under development for the treatment ofRHEA-AIvery positive
02/22/23 4:01 PMNasdaq : ADMP low floatNasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing RequirementsAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatoryRHEA-AIvery positive
11/14/22 4:10 PMNasdaq : ADMP earningslow floatAdamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateAdamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in variousRHEA-AIneutral